Furthermore, these inflammasome‐dependent (early stage gastritis) and inflammasome‐independent (late stage gastric adenocarcinoma) mechanism(s) of action of AIM2 have potential to guide distinct therapeutic strategies against AIM2 at specific stages of the gastric carcinogenesis cascade. Here, AIM2 is linked to gastric adenocarcinoma.